Roche bets $1B+ on DualityBio's ADC tech to tackle TOPO1 resistance

DualityBio said Friday it will receive $45 million upfront from Roche’s Genentech to develop drugs that could be part of a new wave of antibody-drug conjugates. The deal is centered on ...